{"entity":{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","aka":["Shandong New Time Pharmaceutical Co., LTD"],"tldr":"Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent.","summary":"Shandong New Time Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 2, 2/3, 3), testing F182112, F182112 single-agent, Pomalidomide in relapsed or refractory multiple myeloma, relapsed or refractory multiple myeloma (rrmm), cancer of unknown primary site. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Shandong New Time Pharmaceutical","url":"https://clinicaltrials.gov/search?spons=Shandong%20New%20Time%20Pharmaceutical"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07312188","nct07579234","nct07761429"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Shandong, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/shandong-new-time-pharmaceutical/","neighbours":{"trial":[{"id":"nct07579234","kind":"trial","name":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07579234/"},{"id":"nct07761429","kind":"trial","name":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","route":"/trials/nct07761429/"},{"id":"nct07312188","kind":"trial","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07312188/"}]}}